Conformational changes and disease--serpins, prions and Alzheimer's.
暂无分享,去创建一个
[1] K. Waltersson,et al. The crystal structure of Cs[VOF3] · 12H2O , 1979 .
[2] P. Stein,et al. What do dysfunctional serpins tell us about molecular mobility and disease? , 1995, Nature Structural Biology.
[3] J. Griffith,et al. Nature of the Scrapie Agent: Self-replication and Scrapie , 1967, Nature.
[4] Claudio Soto,et al. β-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: Implications for Alzheimer's therapy , 1998, Nature Medicine.
[5] S. Aota,et al. Formation of amyloid-like fibrils by self-association of a partially unfolded fibronectin type III module. , 1998, Journal of molecular biology.
[6] S. Kang,et al. Characterization of a Human α1-Antitrypsin Variant That Is as Stable as Ovalbumin* , 1998, The Journal of Biological Chemistry.
[7] M. Abrahamson,et al. Increased body temperature accelerates aggregation of the Leu-68-->Gln mutant cystatin C, the amyloid-forming protein in hereditary cystatin C amyloid angiopathy. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[8] J. Abrahams,et al. Implications for function and therapy of a 2.9 A structure of binary-complexed antithrombin. , 1998, Journal of molecular biology.
[9] Amyloid β threads in the fabric of Alzheimer's disease , 1998, Nature Medicine.
[10] D Eisenberg,et al. The crystal structure of a 3D domain-swapped dimer of RNase A at a 2.1-A resolution. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[11] S. Prusiner,et al. Prion diseases and the BSE crisis. , 1997, Science.
[12] P. Stein,et al. Biological implications of a 3 A structure of dimeric antithrombin. , 1994, Structure.
[13] S. Eriksson,et al. In vitro amyloid fibril formation from alpha 1-antitrypsin. , 1995, Biological chemistry Hoppe-Seyler.
[14] D. Selkoe,et al. Amyloid β-Protein and the Genetics of Alzheimer's Disease* , 1996, The Journal of Biological Chemistry.
[15] H. Lehmann,et al. Haemoglobin Köln (β–98 Valine → Methionine): An Unstable Protein Causing Inclusion-Body Anaemia , 1966, Nature.
[16] F. Cohen,et al. Prion diseases of humans and animals , 1996 .
[17] R. Carrell,et al. Thromboembolic disease due to thermolabile conformational changes of antithrombin Rouen-VI (187 Asn-->Asp) , 1994, The Journal of clinical investigation.
[18] B. Chesebro. BSE and Prions: Uncertainties About the Agent , 1998, Science.
[19] T. Wight,et al. Perlecan Binds to the β‐Amyloid Proteins (Aβ) of Alzheimer's Disease, Accelerates Aβ Fibril Formation, and Maintains Aβ Fibril Stability , 1997 .
[20] F. Cohen,et al. Prion Protein Biology , 1998, Cell.
[21] W. Hol,et al. The intact and cleaved human antithrombin III complex as a model for serpin–proteinase interactions , 1994, Nature Structural Biology.
[22] J. Whisstock,et al. An atlas of serpin conformations. , 1998, Trends in biochemical sciences.
[23] D. Lomas,et al. The mechanism of Z α1-antitrypsin accumulation in the liver , 1993, Nature.
[24] P. Stein,et al. The biostructural pathology of the serpins: critical function of sheet opening mechanism. , 1996, Biological chemistry Hoppe-Seyler.
[25] F. Cohen,et al. Evidence for protein X binding to a discontinuous epitope on the cellular prion protein during scrapie prion propagation. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[26] R. Kisilevsky,et al. Temporal relationship between glycosaminoglycan accumulation and amyloid deposition during experimental amyloidosis. A histochemical study. , 1985, Laboratory investigation; a journal of technical methods and pathology.
[27] J. Hofrichter,et al. Sickle cell hemoglobin polymerization. , 1990, Advances in protein chemistry.
[28] C. Masters,et al. Tangle disentanglement , 1996, Nature.
[29] Christopher M. Dobson,et al. Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis , 1997, Nature.
[30] R. Crowther,et al. Assembly of microtubule-associated protein tau into Alzheimer-like filaments induced by sulphated glycosaminoglycans , 1996, Nature.
[31] A. Aguzzi,et al. Prion research: the next frontiers , 1997, Nature.
[32] F E Cohen,et al. The prion folding problem. , 1997, Current opinion in structural biology.
[33] P. Gettins,et al. Mapping the Serpin-Proteinase Complex Using Single Cysteine Variants of α1-Proteinase Inhibitor Pittsburgh* , 1998, The Journal of Biological Chemistry.
[34] M. Laurent. Autocatalytic processes in cooperative mechanisms of prion diseases , 1997, FEBS letters.
[35] Ronald C. Petersen,et al. Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17 , 1998, Nature.
[36] L. Serpell,et al. Common core structure of amyloid fibrils by synchrotron X-ray diffraction. , 1997, Journal of molecular biology.
[37] P. Björquist,et al. Identification of the binding site for a low-molecular-weight inhibitor of plasminogen activator inhibitor type 1 by site-directed mutagenesis. , 1998, Biochemistry.
[38] D. Musil,et al. Interfering with the inhibitory mechanism of serpins: crystal structure of a complex formed between cleaved plasminogen activator inhibitor type 1 and a reactive-centre loop peptide. , 1998, Structure.
[39] Martin Rossor,et al. A new variant of prion disease , 1996, The Lancet.
[40] D. Lomas,et al. Latent α1-Antichymotrypsin , 1998, The Journal of Biological Chemistry.
[41] J. Kelly,et al. Alternative conformations of amyloidogenic proteins govern their behavior. , 1996, Current opinion in structural biology.
[42] D. Lomas,et al. Alpha1-antitrypsin deficiency, cirrhosis and emphysema , 1998 .
[43] J. Kelly,et al. The alternative conformations of amyloidogenic proteins and their multi-step assembly pathways. , 1998, Current opinion in structural biology.
[44] Bruce A. Yanker. New clues to Alzheimer's disease: Unraveling the roles of amyloid and tau , 1996, Nature Medicine.
[45] E. Goldsmith,et al. Structural basis of latency in plasminogen activator inhibitor-1 , 1992, Nature.
[46] P. Fraser,et al. Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: implications for Alzheimer's disease , 1995, Nature Medicine.
[47] Bruce A. Yankner,et al. Aging renders the brain vulnerable to amyloid β-protein neurotoxicity , 1998, Nature Medicine.
[48] C. Laurell,et al. The Electrophoretic α;1-Globulin Pattern of Serum in α;1-Antitrypsin Deficiency , 1963 .
[49] J. Abrahams,et al. Inhibitory conformation of the reactive loop of α1-antitrypsin , 1996, Nature Structural Biology.
[50] G. Glenner. Amyloid deposits and amyloidosis. The beta-fibrilloses (first of two parts). , 1980, The New England journal of medicine.
[51] J. Abrahams,et al. The anticoagulant activation of antithrombin by heparin. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[52] Aiwu Zhou,et al. Antithrombins Wibble and Wobble (T85M/K): archetypal conformational diseases with in vivo latent-transition, thrombosis, and heparin activation. , 1998, Blood.
[53] D. Lawrence,et al. Molecular evolution of plasminogen activator inhibitor‐1 functional stability. , 1995, The EMBO journal.
[54] J. Abrahams,et al. Wild-type alpha 1-antitrypsin is in the canonical inhibitory conformation. , 1998, Journal of molecular biology.
[55] M. Skinner,et al. Characterization of the Amyloid Fibril as a Cross-β Protein∗ , 1969, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.